Lenalidomide Grindeks

Lenalidomide, the active ingredient in Lenalidomide Grindeks, is an immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of multiple myeloma and myelodysplastic syndromes with del(5q) in adult patients.

GNH USA supplies Lenalidomide Grindeks as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, transplant centres and pharmacies worldwide.

Lenalidomide Grindeks belongs to the immunomodulatory drug class and is used in hematologic malignancies.

Multiple myeloma (relapsed or refractory): improves response rates and prolongs progression‑free survival. Multiple myeloma (newly diagnosed): used in combination regimens to enhance treatment efficacy. Myelodysplastic syndromes with del(5q): reduces transfusion dependence and improves peripheral blood counts.

Lenalidomide may cause a range of adverse reactions.

Common Side Effects: - Fatigue - Neutropenia - Thrombocytopenia - Anemia - Constipation - Rash

Serious or Rare Side Effects: - Venous thromboembolism - Severe neutropenia or thrombocytopenia leading to infection or bleeding - Tumor lysis syndrome - Secondary primary malignancies - Severe allergic reactions (e.g., Stevens‑Johnson syndrome) - Cardiac arrhythmias

Before initiating therapy, several safety considerations are required.

Pregnancy risk: contraindicated in pregnancy (Category X) and requires effective contraception. Thromboembolic risk: assess patient history and consider prophylactic anticoagulation when appropriate. Hematologic monitoring: perform regular complete blood counts to detect neutropenia, anemia, or thrombocytopenia. Renal function: evaluate and adjust use in patients with severe renal impairment. Drug interactions: avoid concomitant use with strong CYP3A4 inducers. Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original container.

Lenalidomide can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin): may markedly reduce lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Antiplatelet agents (e.g., aspirin): monitor for bleeding tendencies. - Other immunomodulatory agents (e.g., thalidomide): may increase hematologic toxicity. - Drugs that prolong QT interval: monitor ECG and electrolytes.